EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

Frank A Sinicrope iD, Fang-Shu Ou, Dirk Arnold, Walter R Peters, Robert J Behrens, Christopher H Lieu, Khalid Matin, Deirdre J Cohen, Samara L Potter, Andrew B Nixon, Lisa A Kottschade, Emily Kathol und 11 weitere

New England Journal of Medicine · 26.03.2026 · 394 (12) · 1155-1166

DOI: 10.1056/nejmoa2507874 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 26.03.2026. Verfasst von Frank A Sinicrope und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, DNA Mismatch Repair. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Alliance for Clinical Trials in Oncology Operation, The Alliance NCTN Biorepository and Biospecimen Resource Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine-plus-oxaliplatin regimen. Whether the addition of atezolizumab (an anti-programmed death ligand 1 agent) to a modified FOLFOX6 regimen (fluorouracil, oxaliplatin, and leucovorin; called mFOLFOX6) would improve outcomes in patients with stage III colon cancer with mismatch repair-deficient (dMMR) status is unclear. METHODS: In a phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with resected stage III dMMR tumors to receive either adjuvant atezolizumab plus mFOLFOX6 for 6 months, with atezolizumab continued as monotherapy (for a total of 12 months of therapy), or mFOLFOX6 alone for 6 months. The primary end point was disease-free survival. Secondary end points were overall survival and the adverse-event profile. RESULTS: A total of 355 patients were assigned to receive atezolizumab plus mFOLFOX6 and 357 to receive mFOLFOX6 alone. The median age of the patients was 64 years, 55.1% were women, and 53.9% had tumors that were T4, N2, or both (indicating high risk). At a median follow-up of 40.9 months, the 3-year disease-free survival was 86.3% (95% confidence interval [CI], 81.8 to 89.8) in the atezolizumab-mFOLFOX6 group, as compared with 76.2% (95% CI, 70.9 to 80.6) in the mFOLFOX6 group (hazard ratio for disease recurrence or death, 0.50; 95% CI, 0.35 to 0.73; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsColonic NeoplasmsDNA Mismatch RepairAdultAgedFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantDisease-Free SurvivalFluorouracilLeucovorinNeoplasm StagingOrganoplatinum CompoundsFollow-Up StudiesB7-H1 AntigenImmune Checkpoint InhibitorsColectomyAdolescentYoung Adult

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabFluorouracilLeucovorinOrganoplatinum CompoundsB7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Mayo Clinic, Rochester, MN.
  • Gastrointestinal Research Unit, Mayo Clinic, Rochester, MN.
  • Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
  • Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany.
  • Baylor University Medical Center, Dallas.
  • Iowa-Wide Oncology Research Coalition National Cancer Institute Community Oncology Research Program, Des Moines.

ORCID-Profile: Frank A Sinicrope

Förderung

  • NCI NIH HHS
  • Alliance for Clinical Trials in Oncology Operation
  • The Alliance NCTN Biorepository and Biospecimen Resource Grant
  • Statistics and Data Management Center for the Alliance for Clinical Trials in Oncology

Zitieren

APA

Sinicrope, F. A., Ou, F. S., Arnold, D., Peters, W. R., Behrens, R. J., Lieu, C. H., Matin, K., Cohen, D. J., Potter, S. L., Nixon, A. B., Kottschade, L. A., Kathol, E., Frankel, W. L., Shergill, A., Hsu, D., Reinacher-Schick, A., Mehan, P., Gold, P. J., Khalil, M. F., …, & Meyerhardt, J. A. (2026). Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer. New England Journal of Medicine, 394(12), 1155-1166. https://doi.org/10.1056/nejmoa2507874

Vancouver

Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, et al. Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer. New England Journal of Medicine. 2026;394(12):1155-1166. doi:10.1056/nejmoa2507874

BibTeX
@article{Sinicrope2026,
  author = {Sinicrope, Frank A and Ou, Fang-Shu and Arnold, Dirk and Peters, Walter R and Behrens, Robert J and Lieu, Christopher H and Matin, Khalid and Cohen, Deirdre J and Potter, Samara L and Nixon, Andrew B and Kottschade, Lisa A and Kathol, Emily and Frankel, Wendy L and Shergill, Ardaman and Hsu, Dennis and Reinacher-Schick, Anke and Mehan, Paul and Gold, Philip J and Khalil, Maged F and Zemla, Tyler and Gatten, Clare and O'Reilly, Eileen M and Meyerhardt, Jeffrey A},
  title = {Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {12},
  pages = {1155--1166},
  doi = {10.1056/nejmoa2507874}
}
Kostenlos starten →